Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients

Background.Serious hyperkalemia was reported in 10 of chronic hemodialysis (HD) patients that could lead to arrhythmia and death. Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) are well accepted for cardio-protective benefits. The relationship between renin-angiotensin system blockade (RASB) and hyperkalemia in chronic HD patients remains controversial. The aim of this study was to find the relationship between RASB and hyperkalemia in these patients.Methods.Pre-dialysis serum potassium, clinical factors, and drugs were evaluated in 200 chronic HD patients in one HD center. Hyperkalemia was defined as serum K ≥ 5.3 meqL. Finally, multivariate analysis with logistic regression was used to evaluate the risk of hyperkalemia by RASB and other factors. Results.In 200 patients, the mean K was 4.93 ± 0.79 meqL, and 70 (35%) patients had hyperkalemia. Fifty-eight (29%) patients were prescribed with RASB. Seven variablesnon-DM, longer HD duration, lower dialysate calcium, lower serum glucose, higher serum iPTH, not using RASB, and not using furosemidewere more frequent in hyperkalemia group. In logistic regression analysis, RASB was associated with decreased odds for hyperkalemia (OR 0.262, p = 0.001 in model A; OR 0.205, p = 0.001 in model B). In addition, furosemide was associated with decreased odds for hyperkalemia (OR 0.068, p 0.022 in model B).Conclusions.RASB is not associated with hyperkalemia in chronic HD patients.